ELVN NASDAQ
Enliven Therapeutics, Inc.
1W: +5.9%
1M: -5.0%
3M: -17.5%
YTD: +181.2%
1Y: +112.0%
3Y: +245.4%
5Y: +193.6%
$43.69
+2.20 (+5.30%)
Weekly Expected Move ±6.8%
$36
$39
$42
$44
$47
Credit Risk of going bust: lower than 83% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.20B.
Distance to default 10.64 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.3%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.20B.
Distance to default 10.64 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.3%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-07-29
Earliest Filing
2023-06-26
Latest Filing
partner: 4
acquirer: 3
target: 1
Counterparties (Filed by ELVN)
8 relationshipsCompanies named in ELVN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Sales agent for Open Market Sale Agreement | 2023-06-26 | View |
| Cantor Fitzgerald | — | partner | Previous sales agent for Controlled Equity Offering Sales Agreement | 2023-06-26 | View |
| Cardurion Pharmaceuticals, Inc. | — | partner | Counterparty in the Asset Purchase Agreement for the sale of tovinontrine (IMR-687) and other assets related to the PDE9 | 2023-03-01 | View |
| Cardurion Pharmaceuticals, Inc. | — | acquirer | Acquired Imara Inc.'s PDE9 program assets including tovinontrine (IMR-687) for an upfront payment of $34.75 million plus | 2022-11-10 | View |
| Enliven Therapeutics, Inc. | ELVN | target | Target company in a merger agreement with Imara Inc. | 2022-10-13 | View |
| Iguana Merger Sub, Inc. | — | acquirer | Wholly-owned subsidiary of Imara Inc. used as the merger vehicle. | 2022-10-13 | View |
| Cardurion Pharmaceuticals, Inc. | — | acquirer | Acquired IMRA Inc.'s PDE9 program assets including tovinontrine (IMR-687) for an upfront payment of $34.75 million plus | 2022-09-07 | View |
| Columbia REIT – 116 Huntington, LLC | — | partner | Landlord entering into lease termination agreement with IMARA Inc. | 2022-07-29 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-14 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-06-12 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-06-11 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-10 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-07 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-12-11 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-25 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-16 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-06-13 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-18 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR